the aim of the study was to assess angiogenesis markers -endostatin and endothelial growth factor (EGF) as markers of detection of gastric carcinoma. material and methods. The study involved 20 patients with colorectal cancer (10 women, 10 men) aged 35 -75 years, mean age = 55 years ± 11.2 who referred to the 2 nd Department of General Surgery, Medical University in Lublin between June 2008 and June 2009. The control group comprised 10 volunteers (6 women, 4 men) who underwent upper gastrointestinal (GI) endoscopy due to the reflux disease and in whom gastric cancer was not diagnosed. Results. The mean endostatin concentration in controls was 5.21 ng/mL ± 1.37. Mean concentrations in patients with gastric cancer were higher than those in controls -5.91 ng/mL ± 1.5. The difference was not statistically significant (p= 0.714). The EGF concentration in the control group was 28.19 pg/mL ± 12.94. EGF concentrations in patients with gastric cancer were higher compared to the control group -28.8 pg/mL ± 12.63. The difference was not statistically significant (p= 0.85). The mean concentration of endostatin before the operation was 5.91 ng/mL ± 1.5 and after surgery was 5.33 ng/mL ± 2.01, the difference was not statistically significant. conclusions. Blood endostatin and EGF quantitative determinations probably is not useful for detection of gastric carcinoma and effectiveness of treatment.
The early detection of gastric cancer has a great influence on the effectiveness of treatment. It has been proved that gastric cancer diagnosed in advanced stage has worse prognosis than when detected in the early stage (cancer infiltration limited to the mucosal and submucosal layer; not related to the extend of lesion and the presence of metastases) (1) . Gastric cancer is the third cause of cancer-related death in the world (after lung cancer and colon cancer) (1) . The 5-year survival is observed in 50% of patients with advanced cancer and in 95% of early diagnosed patients (1) . The main cause of such a high mortality from gastric cancer are difficulties in early diagnosis due to the non-specific manifestation of the disease. In Poland in 2007 year, 5246 new cases and 5610 deaths were noticed due to the malignant gastric cancer (The National Cancer Registry of Poland) (2), the 5-year survival was observed in 10-25% of patients (2, 3) . The effectiveness of surgery, considered as primary treatment and its radicalness depends on the stage of the cancer. Detailed medical history and different diagnostic methods can be useful in the early diagnosis.
In 1971, Folkman suggested that tumour growth and expansion are closely related to the development of a network of blood vessels within the tumour (4) . Angiogenesis involves a number of stimulators (cytokines, chemokins, growth factors) and endogenous inhibitors (4) . Determinations of angiogenesis markers, including epidermal growth factor, in serum may 43 Evaluation of endostatin and egf serum levels in patients with gastric cancer be useful for monitoring the course of disease and effectiveness of cancer treatment (4). Studies on inhibitors of angiogenesis, including endostatin and antibodies directed against the promoter receptors, focus on novel methods of angiogenic therapy of cancers.
The aim of this study was to assess angiogenesis markers -endostatin and endothelial growth factor (EGF) as markers of detection of gastric carcinoma.
MATERIAL AND METHoDS
The study involved 20 patients with colorectal cancer (10 women, 10 men) aged 35 -75 years, mean age = 55 years ± 11,2. The control group comprised 10 volunteers (6 women, 4 men) who underwent upper gastrointestinal (GI) endoscopy due to the reflux disease and in whom gastric cancer was not diagnosed. According to the Lauren classification, the diffuse-type gastric cancer was diagnosed in 13 patients (65%), intestinal-type cancer in 6 patients (30%), the mixed-type cancer in 1 person. In 25% patients of the study group, histological differentiation (grading, G trait) was assessed as 2, and in the remaining 75% as 3. The TNM stages (tab. 1 and 2) were as follows: three patients (~15%) stage I, three patients (~ 15%) stage II, two (~ 10%) -stage III, and remaining twelve patients (~ 60%) -stage IV.
Patients with gastric cancer underwent upper GI endoscopy with biopsies, abdominal CT, abdominal US, chest X-ray, full blood tests, coagulometry; levels of electrolytes and renal parameters were determined. Blood samples were taken from the ulnar vein one day before and 5 days after surgery.
The blood was centrifuged 1 hour after collecting. The obtained serum was stored at -72ºC until use. Determinations were performed using enzyme-linked immunosorbent assay (ELISA) with Quantikine Human Endostatin Immunoassay (Catalog Number DNST0) of R&D Systems and Quantikine Human EGF Immunoassay (Catalog Number DEG00, SEG00, PDEG00) of R&D. The results were statistical analysed with STATISTICA 7.0.
RESULTS
The mean endostatin concentration in controls was 5.21 ng/mL ± 1.37. Mean concentrations in patients with gastric cancer were The mean serum concentration of EGF in patients with intestinal-type cancer was 36.07 pg/mL ± 16.73. Mean concentrations in patients with diffuse-type cancer were lower than those in intestinal type -27.31 pg/mL ± 11.79. The difference was not statistically significant (p= 0.19) -tab. 5. The correlation between the histological differentiation (grading, G trait) and serum concentrations of endostatin was statistically significant (p=0.04) -tab. 5. The mean serum concentration of endostatin in patients with grade II was 8.37 ng/mL ± 0.34, in patients with grade III was 4.95 ng/mL ± 2.2. The difference was statistically significant (p=0.04) (tab. 5). The mean serum concentration of EGF in patients with grade II was 17.4 pg/mL ± 2.01 and with grade III was 30.28 pg/mL ± 13.5. The difference was not statistically significant because of the high standard deviation (p=0.2) -tab. 5. The mean concentration of endostatin before the operation was 5.91 ng/mL ± 1.5 and after surgery was 5.33 ng/mL ± 2.01, the difference was not statistically significant.
DISCUSSIoN
Endostatin is a well-known anti-growth factor and anti-endothelial cells migration factor (5). It is considered an angiogenesis inhibitor, potentially able to reduce the blood supply required for the neoplasm development (6) . Endostatin was primarily isolated from mouse hemangiothelioma cells (EoMA) as a part of proteolysed type VIII collagen with a molecular weight of 20 kDa (6). Potential anti-neoplastic effects of endostatin were best described in animal models. Almost total complete regression of different types of neoplastic tumours, including lung cancer, fibrosarcoma, melanoma, EoMA, was observed after mouse endostatin. Further studies showed that human endostatin has similar effects in various animal models (7, 8) . Higher levels of circulating endostatin were detected in histologically various forms of neoplasms, e,g, breast cancer, renal cancer, ovarian cancer, endometrial cancer, sarcomas, acute myeloid leukaemia, non-Hodgkin's lymphoma, non-small cell lung carcinoma, pancreatic cancer, liver cancer, thyroid cancer, head and neck cancer (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . In this study, higher serum concentration of circulating endostatin was detected in patients with gastric cancer compared to the control group. The difference was not statistically significant (tab. 3). The post-treatment levels of circulating endostatin were found to be lower in patients with various histological forms of neoplasms. Such a correlation was observed in patients with acute myeloid leukaemia after chemotherapy, in women with endometrial cancer after surgery and in patients with non-small cell lung carcinoma after surgery (18, 21, 30) . In the authors' study, a similar correlation was demonstrated. The post-operative levels of endostatin in the study group were lower than those before surgery but the differences were not statistically significant -tab. 4. Lack of the statistical significance can result from too short period between surgery and blood collecting (5 days). Suzuki et al. proved a high correlation between endostatin concentrations in patients with non-small cell lung carcinoma after surgery and T and N grades (21). Authors of this study did not observed this correlation -tab. 5, but they observed a correlation between grading and the mean serum level of endostatin. The higher serum concentration of circulating endostatin was detected in patients with grade III gastric cancer compared to the patients with grade II -tab. 5.
EGF is a polypeptide isolated from submandibular glands of Swiss Webster mice by Stanley Cohen in 1960. Early opening of the eyes, growth of the incisors, inhibition of hair growth were triggered by the injection of EGF to newborn mice (9, 10) . EGF belongs to growth factors binding 170 kDa receptor molecule. The endothelial growth factor receptor (EGFR) is a transmembrane receptor, a 170 kDa glycoprotein. The EGFR receptor protein contains extracellular ligand-binding domain, transmembrane region, intracellular domain with tyrosine kinase internal activity. EGF (epithelial growth factor) and TGF α (transforming growth factor alfa) are two main EGFR -activating endogenous ligands (11) .
According to literature data, the serum EGF level depends on the histological types of neoplasm. The EGF concentrations in women with endometrial cancer (Tomaszewski et al.) and in men with thyroid cancer (Konturek et al.) were lower compared to controls (27, 28). Tomaszewski et al. suggested that low serum EGF concentrations and low EGFR expression could reduce the risk of endometrial cancer (27). In the study by Konturek et al., serum EGF concentrations correlated with and clinical severity of thyroid cancer according to TNM staging -the higher the stage, the higher the EGF serum concentration (28). otherwise, serum EGF levels were lower in patients with stomach cancer and breast cancer compared to control groups. Pawlikowski et al. observed that low serum EGF concentrations in patients with stomach cancer correlated with higher risk of this neoplasm (29). In authors' study, mean EGF serum concentrations in patients with gastric cancer were similar to those in a control group. The study carried out by Chinese researchers in the group of 600 women with breast cancer showed that mean EGF concentrations in patients were markedly lower than those in controls. The authors suggested that EGF could be a protective factor for breast cancer (30) . According to them, low serum EGF concentrations observed in patients with breast cancer resulted from binding of EGF particles with endothelial growth factor receptors (EGFRs) present in cancer cells whereas increased EGF concentrations after chemotherapy were associated with the response to treatment -reduced number of cancer cells led to a decrease in the number of EGFRs and an increase in free EGF. A similar correlation was not observed in this study -the mean EGF serum concentrations in patients with gastric cancer after resection were similar to those before surgery. In this study, serum concentrations of endostatin and EGF in patients with gastric cancer were assessed statistically depending on the disease stage according to TNM classification, the histologic tumor grade score (grading) and Lauren classification -intestinal or diffuse type - Table  5 . We observed statistically significant difference between the endostatin serum concentrations in patients with grade 2 and 3 gastric cancer. The mean serum concentration of endostatin in patients with grade 3 cancer was significantly higher than in grade 2.
Blood endostatin and EGF quantitative determinations probably is not useful for early detection of gastric carcinoma and effectiveness of treatment.
This study was performed in a small group of volunteers and blood was collected early, on fifth post-operative day; therefore, further studies should be carried out in larger populations and over longer postoperative periods.
